Issue of Equity in lieu of Non-Exec Director Fees | 18-Jul-2025 | 07:00 | RNS |
Holding(s) in Company | 09-Jul-2025 | 14:53 | RNS |
Posting of Circular and Notice of General Meeting | 08-Jul-2025 | 07:00 | RNS |
Placing to raise £2.0 million | 04-Jul-2025 | 07:00 | RNS |
Liver fibrosis breakthrough with Optimer® p... | 30-Jun-2025 | 07:00 | RNS |
Agreement with global life sciences leader | 25-Jun-2025 | 07:00 | RNS |
Unilever second Optimer development programme | 30-May-2025 | 07:00 | RNS |
Aptamer Announces New Data at ASGCT | 15-May-2025 | 07:01 | RNS |
Optimer licensing agreements and repeat contracts | 15-May-2025 | 07:00 | RNS |
Alzheimer’s test advanced and royalty agre... | 06-May-2025 | 07:00 | RNS |
Licensing agreed for Optimer as vaccine adjuvant | 30-Apr-2025 | 07:00 | RNS |
Interim Results | 11-Mar-2025 | 07:00 | RNS |
TR-1: Standard form notification of major holdings | 27-Feb-2025 | 12:50 | RNS |
Block Listing Interim Review | 25-Feb-2025 | 07:01 | RNS |
Notice of Results and Investor Presentation | 25-Feb-2025 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 0.38p |
Change Today | -0.015p |
% Change | -3.80 % |
52 Week High | 0.58 |
52 Week Low | 0.21 |
Volume | 14,139,967 |
Shares Issued | 2,391.76m |
Market Cap | £9.09m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
14:15 | 127,837 @ 0.39p |
13:07 | 2,468,025 @ 0.37p |
12:38 | 1,949,476 @ 0.38p |
12:34 | 2,105,264 @ 0.38p |
12:33 | 2,052,808 @ 0.39p |
CEO | Arron Tolley |
CFO | Andrew Rapson |
You are here: research